ArticleJournal of family medicine and primary care2022
Plethora of adverse drug reactions in geriatric population receiving statin therapy for dyslipidaemia.
Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperlipidemia plays a major role in the pathogenesis of cardiovascular diseases (CVD). Statins are considered to be the most efficacious drugs in the management of hyperlipidemia and this class of drugs is most commonly prescribed for the treatment of hyperlipidemias. Although statin therapy has transformed the management of hyperlipidemia, it is associated with the skeletal muscle, neurological, and metabolic adverse effects. This study was conducted to evaluate the adverse effects of statin therapy in a geriatric population which may help in understanding whether these effects are dose-dependent. Methods: The study was conducted on 200 patients receiving statin therapy (atorvastatin and rosuvastatin) for hyperlipidemias. They were divided into four groups depending on the prescribed dose of atorvastatin and rosuvastatin. All study subjects were followed up for 6 months. The adverse effects reported by them during the statin therapy were documented and analyzed. Results: All patients reported adverse effects after the initiation of statin therapy. Headache and muscle symptoms were among the most commonly reported adverse effects. There was no serious adverse effect (SAE). None of the adverse effects led to the discontinuation of the statin therapy. Conclusion: The results of this study suggest that all patients receiving statin therapy experience one or more adverse effects during the therapy. The adverse effects were not found to be severe in the geriatric age group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.